The combination of the programmed cell death-ligand 1 (PD-L1) inhibitor atezolizumab and the vascular endothelial growth factor A (VEGFA) inhibitor bevacizumab (atezo-bev) has become a recommended first-line therapy for advanced HCC, alongside the dual checkpoint inhibitor combination of durvalumab and tremelimumab (durva-treme) [5]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.